Today, the FDA approved a combination of two drugs—acalabrutinib (Calquence) and venetoclax (Venclexta)—to treat untreated chronic lymphocytic leukemia (CLL).[1] It is the first oral fixed-duration combination intended for first-line patients.[1] The approval follows results from the phase 3 AMPLIFY clinical trial, which demonstrated that this combination reduced the risk of progression or death by 35% compared with chemoimmunotherapy (HR 0.65; P = 0.0004).[3] The overall response rate was 92.8% in venetoclax patients compared to 75.2% in chemoimmunotherapy patients.[2] Fifty-six-month progression-free survival was 75.9% versus 64.5% with standard treatment.[2] An important advantage is that it is an oral regimen with a fixed duration, which allows patients the option of a break in treatment.[1] This approval represents a significant advance in the treatment of CLL and expands choices for patients and physicians.[1]